The Cigna Group (CI) Stock Forecast & Price Target

$340.43

+0.16 (+0.05%)

(As of 09:46 AM ET)

The Cigna Group - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 15 Analyst Ratings

Sell
0

Hold
1

Buy
14

Based on 15 Wall Street analysts who have issued ratings for The Cigna Group in the last 12 months, the stock has a consensus rating of "Buy." Out of the 15 analysts, 1 has given a hold rating, 13 have given a buy rating, and 1 has given a strong buy rating for CI.

Consensus Price Target

$392.79
15.38% Upside

According to the 15 analysts' twelve-month price targets for The Cigna Group, the average price target is $392.79. The highest price target for CI is $438.00, while the lowest price target for CI is $348.00. The average price target represents a forecasted upside of 15.38% from the current price of $340.43.

Get the Latest News and Ratings for CI and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for The Cigna Group and its competitors.

CI Analyst Ratings Over Time

Type	Current Forecast 10/9/23 to 10/8/24	1 Month Ago 9/9/23 to 9/8/24	3 Months Ago 7/11/23 to 7/10/24	1 Year Ago 10/9/22 to 10/9/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	13 Buy rating(s)	13 Buy rating(s)	13 Buy rating(s)	6 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$392.79	$384.86	$376.20	$339.11
Forecasted Upside	15.38% Upside	8.87% Upside	14.06% Upside	17.07% Upside
Consensus Rating	Buy	Buy	Buy	Moderate Buy

Don't Pay a Dime for Marc Lichtenfeld's Top AI Picks (Ad)

Usually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research... But today, the author of Get Rich with Dividends is feeling extra generous...

Click here now to claim your FREE copy of Marc's AI playbook.

CI Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

The Cigna Group Stock vs. The Competition

Type	The Cigna Group	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.78	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	15.43% Upside	10,685.01% Upside	7.99% Upside
News Sentiment Rating	Positive News See Recent CI News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/1/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$400.00 ➝ $400.00	+14.46%
9/17/2024	Jefferies Financial Group 2 of 5 stars		Boost Target	Buy ➝ Buy	$402.00 ➝ $422.00	+16.25%
9/9/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$384.00 ➝ $384.00	+8.05%
8/21/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$435.00 ➝ $438.00	+27.49%
8/2/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$410.00 ➝ $410.00	+22.37%
8/2/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$393.00 ➝ $405.00	+24.64%
Get the Latest News and Ratings for CI and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for The Cigna Group and its competitors with MarketBeat's FREE daily newsletter.
6/26/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$400.00	+18.06%
5/30/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$388.00	+16.54%
5/3/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$370.00 ➝ $400.00	+18.29%
3/4/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$382.00 ➝ $392.00	+16.52%
2/6/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$334.00 ➝ $348.00	+6.18%
2/5/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$360.00 ➝ $370.00	+14.41%
2/1/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$355.00 ➝ $370.00	+22.90%
1/4/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$330.00 ➝ $372.00	+22.53%
8/17/2023	Edward Jones Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
8/7/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Strong-Buy ➝ Strong-Buy	$310.00 ➝ $330.00	+15.15%
8/4/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$320.00 ➝ $350.00	+21.48%
6/20/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$375.00 ➝ $365.00	+35.77%
2/8/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$335.00 ➝ $309.00	+6.92%
2/8/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform	$309.00 ➝ $335.00	+15.92%
2/6/2023	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$350.00 ➝ $320.00	+9.35%
11/7/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$329.00 ➝ $385.00	+19.52%
11/7/2022	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$329.00 ➝ $368.00	+14.24%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:17 AM ET.

Should I Buy The Cigna Group Stock? CI Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, October 1, 2024. Please send any questions or comments about these The Cigna Group pros and cons to contact@marketbeat.com.

The Cigna Group
Bull Case

Here are some ways that investors could benefit from investing in The Cigna Group:

The Cigna Group's stock has an "overweight" rating reaffirmed by Cantor Fitzgerald with a target price of $400.00, suggesting a potential upside of 14.91% from the current price. This indicates positive sentiment from analysts towards the company's future performance.
Institutional investors like Vanguard Group Inc., Price T Rowe Associates Inc. MD, and Sanders Capital LLC have significantly increased their stakes in The Cigna Group, showing confidence in the company's growth prospects.
The company has a strong market capitalization of $98.89 billion, indicating stability and financial strength in the market.
The Cigna Group has a low debt-to-equity ratio of 0.73, which signifies a healthy balance sheet and lower financial risk for investors.
The stock has shown consistent trading performance with a 50-day simple moving average of $348.38 and a 200-day simple moving average of $345.28, reflecting stability in its price trends.

The Cigna Group
Bear Case

Investors should be bearish about investing in The Cigna Group for these reasons:

Despite positive analyst ratings, the stock has a PE ratio of 28.72, which may indicate that the stock is relatively expensive compared to its earnings, potentially limiting short-term gains for investors.
The company's 1-year high of $370.83 suggests that the stock may be nearing its peak valuation, posing a risk for investors looking for significant capital appreciation.
With 86.99% of the company's stock owned by institutional investors and hedge funds, individual investors may have limited influence on the company's strategic decisions and future direction.
The price-to-earnings-growth ratio of 1.08 may indicate that the stock is not undervalued based on its growth prospects, potentially limiting long-term returns for investors.
While the company has a consensus rating of "Buy," investors should consider the potential impact of any changes in the healthcare industry or regulatory environment on The Cigna Group's future performance.

CI Forecast - Frequently Asked Questions

: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for The Cigna Group is $392.79, with a high forecast of $438.00 and a low forecast of $348.00.
: 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for The Cigna Group in the last year. There is currently 1 hold rating, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CI shares.
: According to analysts, The Cigna Group's stock has a predicted upside of 15.38% based on their 12-month stock forecasts.
: The Cigna Group has been rated by research analysts at Barclays, Cantor Fitzgerald, Jefferies Financial Group, JPMorgan Chase & Co., Royal Bank of Canada, and Stephens in the past 90 days.
: Analysts like The Cigna Group more than other "medical" companies. The consensus rating for The Cigna Group is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CI compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

The most important AI company you've never heard of (Ad)

Because this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, Google and others are lining up to get this company's products.

Get the full story on this secret AI company poised for massive growth

This page (NYSE:CI) was last updated on 10/8/2024 by MarketBeat.com Staff

From Our Partners